Asco 2019 – the case for Nektar sweetens, slightly
Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
Asco 2019 – Abstract drop fires the starting gun
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Licensing deal activity follows buyout market downwards
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
JP Morgan 2019 day two roundup – after the party a harsh reality
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
SITC 2018 – Nektar’s big reveal falls flat
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
SITC 2018 – No honey for Nektar
The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.
SITC event – Nektar hopes to pivot away from Incyte's failure
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.